Developing a new malaria vaccine to block transmission
Rationally-Designed, Spontaneous-Particleized Pfs48/45 for a Multivalent Malaria Vaccine
This study is working on a new malaria vaccine that could help stop the disease from spreading by teaching the body to make antibodies against a specific protein in mosquitoes, and it's aimed at people who want to help in the fight against malaria.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-10834979 on NIH RePORTER |
What this research studies
This research focuses on creating a malaria vaccine that prevents the transmission of the disease by inducing antibodies that block the malaria parasite's development in mosquitoes. The team is working on a specific protein, Pfs48/45, which has shown promise as a vaccine candidate but has not yet been tested in humans. By enhancing the production of this protein and understanding its structure, the researchers aim to design a more effective vaccine that can be combined with a special adjuvant to boost its effectiveness. This approach is part of a broader effort to accelerate the discovery of new malaria vaccines.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals at risk of malaria infection, particularly those living in endemic regions.
Not a fit: Patients who are not at risk of malaria or those who have already been vaccinated against malaria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a highly effective malaria vaccine that significantly reduces the spread of the disease.
How similar studies have performed: Other research has shown promise in developing transmission-blocking vaccines, but this specific approach using Pfs48/45 is relatively novel.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Lovell, Jonathan F — State University of New York at Buffalo
- Study coordinator: Lovell, Jonathan F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.